Lepius Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 16-11-2024
- Paid Up Capital ₹ 0.10 M
as on 16-11-2024
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -27.86%
(FY 2023)
- Profit 40.00%
(FY 2023)
- Ebitda 806.90%
(FY 2023)
- Net Worth 3.67%
(FY 2023)
- Total Assets 7.59%
(FY 2023)
About Lepius Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Chandreshbhai Bhut, Krunal Patel, Nileshkumar Ahir, and One other member serve as directors at the Company.
- CIN/LLPIN
U74999GJ2016PTC092527
- Company No.
092527
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Jun 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Lepius Life Sciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nileshkumar Ahir  | Director | 17-Jun-2016 | Current |
| Chandreshbhai Bhut | Director | 17-Jun-2016 | Current |
| Krunal Patel | Director | 17-Jun-2016 | Current |
| Bhagyeshkumar Patel | Director | 17-Jun-2016 | Current |
Financial Performance of Lepius Life Sciences.
Lepius Life Sciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 27.86% decrease. The company also saw a substantial improvement in profitability, with a 40% increase in profit. The company's net worth moved up by a moderate rise of 3.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lepius Life Sciences?
In 2023, Lepius Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Labh Minstone Private LimitedActive 6 years 4 monthsChandreshbhai Bhut and Krunal Patel are mutual person
- Solitude Lifesciences Private LimitedActive 4 years 4 months
Chandreshbhai Bhut, Krunal Patel and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Lepius Life Sciences?
Lepius Life Sciences has a workforce of 23 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lepius Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lepius Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
